Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Belzutifan, a Potent HIF2α Inhibitor, in the Pacak-Zhuang Syndrome.
Journal: The New England journal of medicine
Published: November 24, 2021
Author Correction: Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.
Journal: Nature medicine
Published: August 28, 2021
Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 20, 2017
Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 08, 2016
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Journal: The New England journal of medicine
Published: December 09, 2014
Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 17, 2014
Showing 1-8 of 8
Last Updated: 09/26/2026